13F

Stock

Neuphoria Therapeutics Inc.

NEUP · held by 21 managers

Reported value

$5.59M

Holders

21

+1 new · −0 exited

Holders’ est. mark

−$39K

Price effect on 3 books still in the name

Largest holder

$3.4M

Lynx1 Capital Management LP

Notable conviction

Share of each notable manager’s 13F book.

Holder count by quarter

Who holds it

Notable only
InvestorSharesValueEst. markChange
Lynx1 Capital Management LP875.2K$3.4M—Held
Shay Capital LLC169.1K$655.9K—Held
AdvisorShares Investments LLC134.2K$520.7K—Held
DIADEMA PARTNERS LP50K$194K—Held
Ikarian Capital, LLC47.4K$184.1K—Held
ADAR1 Capital Management, LLC30K$116.4K—Held
Vanguard20.9K$81.3K—Held
GEODE CAPITAL MANAGEMENT, LLC17.3K$67.1K—Held
JANE STREET GROUP, LLC16.6K$64.4K—Held
BRIDGEWAY CAPITAL MANAGEMENT, LLC14.8K$57.2K—Held
BOOTHBAY FUND MANAGEMENT, LLC14K$54.3K—Held
Persistent Asset Partners Ltd13.4K$52K−$38.8KCut−$5.86K
XTX Topco Ltd12K$46.6K—Held
COMMONWEALTH EQUITY SERVICES, LLC11.2K$43.5K—Held
Merck & Co., Inc.10K$38.9K—Held
UBS Group AG1.65K$6.41K—Held
Tower Research Capital LLC (TRC)1.4K$5.43K—Held
RHUMBLINE ADVISERS202$783—Held
MORGAN STANLEY58$225−$56Added$142
FNY Investment Advisers, LLC26.5K$102—New
BANK OF AMERICA CORP /DE/18$70−$135Cut−$131

Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.